latest update:
[TrialBase DB]

trial summary · NCT07169630

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Alzheimer s Disease, sponsored by National Institute of Mental Health (NIMH). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07169630phase PHASE1enrollment 90start 2026-11-04

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI. Objective: To test whether medical imaging using a new radiotracer (\[18F\]PF-06445974) can measure PDE4B in the brains of people with AD or MCI. Eligibility: People aged 50 years and older with AD or MCI. Healthy volunteers are also needed. Design: Participants will have up to 5 clinic visits with 3 imaging scans of the brain. They will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory. Participants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each. Participants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 …

Source record: https://clinicaltrials.gov/study/NCT07169630

Facts

registry idNCT07169630
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionAlzheimer s Disease
sponsorNational Institute of Mental Health (NIMH)
sponsor classNIH
enrollment90
start date2026-11-04
primary completion2029-04-11
completion2030-04-11
results postednot reported

Conditions

  • Alzheimer s Disease
  • Mild Cognitive Impairment
  • Healthy

Interventions

  • 18F-PF974
  • 18F-florbetaben

Countries

  • United States

Intervention types: DRUG

Work with this record